Literature DB >> 22555278

The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire.

Amit S Patel1, Richard J Siegert, Katherine Brignall, Patrick Gordon, Sophia Steer, Sujal R Desai, Toby M Maher, Elisabetta A Renzoni, Athol U Wells, Irene J Higginson, Surinder S Birring.   

Abstract

RATIONALE: Health status is impaired in patients with interstitial lung disease (ILD). There is a paucity of tools that assess health status in ILD. The objective of this study was to develop and validate the King's Brief Interstitial Lung Disease questionnaire (K-BILD), a new health status measure for patients with ILD.
METHODS: Patients with ILD were recruited from outpatient clinics. The development of the questionnaire consisted of three phases: item generation; item reduction, allocation to domains by factor analysis, Rasch analysis to create unidimensional scales and validation; and repeatability testing.
RESULTS: 173 patients with ILD (49 with idiopathic pulmonary fibrosis) completed a preliminary 71-item questionnaire. 56 items were removed due to redundancy, low factor loadings or poor fit to the Rasch model. The final version of the K-BILD questionnaire consisted of 15 items and three domains (breathlessness and activities, chest symptoms and psychological). Internal consistency assessed with Cronbach's α coefficient was 0.94 for the K-BILD total score. Concurrent validity of the K-BILD questionnaire was high compared with St George's Respiratory Questionnaire (r=0.90) and moderate with lung function (vital capacity, r=0.50). The K-BILD questionnaire was repeatable over 2 weeks (n=44), with intraclass correlation coefficients for domains and total score 0.86-0.94. The K-BILD construct validity for patients with idiopathic pulmonary fibrosis was similar to that of other ILDs.
CONCLUSION: The K-BILD questionnaire is a brief, valid, self-completed health status measure for ILD. It could be used in the clinic to assess ILD from the patients' perspective.

Entities:  

Mesh:

Year:  2012        PMID: 22555278     DOI: 10.1136/thoraxjnl-2012-201581

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  64 in total

Review 1.  Current best practice in rehabilitation in interstitial lung disease.

Authors:  Atsuhito Nakazawa; Narelle S Cox; Anne E Holland
Journal:  Ther Adv Respir Dis       Date:  2016-11-15       Impact factor: 4.031

2.  Outcome Measures for Clinical Trials in Interstitial Lung Diseases.

Authors:  Matthew R Lammi; Robert P Baughman; Surinder S Birring; Anne-Marie Russell; Jay H Ryu; Marybeth Scholand; Oliver Distler; Daphne LeSage; Catherine Sarver; Katerina Antoniou; Kristin B Highland; Otylia Kowal-Bielecka; Joseph A Lasky; Athol U Wells; Lesley Ann Saketkoo
Journal:  Curr Respir Med Rev       Date:  2015

Review 3.  Hypersensitivity pneumonitis.

Authors:  Ulrich Costabel; Yasunari Miyazaki; Annie Pardo; Dirk Koschel; Francesco Bonella; Paolo Spagnolo; Josune Guzman; Christopher J Ryerson; Moises Selman
Journal:  Nat Rev Dis Primers       Date:  2020-08-06       Impact factor: 52.329

4.  Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.

Authors:  Andrew M Wilson; Allan B Clark; Tony Cahn; Edwin R Chilvers; William Fraser; Matthew Hammond; David M Livermore; Toby M Maher; Helen Parfrey; Ann Marie Swart; Susan Stirling; David R Thickett; Moira Whyte
Journal:  JAMA       Date:  2020-12-08       Impact factor: 56.272

Review 5.  Optimizing quality of life in patients with idiopathic pulmonary fibrosis.

Authors:  Mirjam J G van Manen; J J Miranda Geelhoed; Nelleke C Tak; Marlies S Wijsenbeek
Journal:  Ther Adv Respir Dis       Date:  2017-01-01       Impact factor: 4.031

6.  Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch.

Authors:  Monique Wapenaar; Amit S Patel; Surinder S Birring; Ron T van Domburg; Eric Wp Bakker; Virginia Vindigni; C Magnus Sköld; Vincent Cottin; Carlo Vancheri; Marlies S Wijsenbeek
Journal:  Chron Respir Dis       Date:  2016-12-26       Impact factor: 2.444

7.  Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France.

Authors:  Yannick Allanore; Joel Constans; Dominique Godard; Gerard de Pouvourville; Stephane Bouee; Viviane Jeanbat; Clement Teissier; Katell Le Lay; Julien Chollet; Eric Hachulla
Journal:  J Scleroderma Relat Disord       Date:  2021-06-21

Review 8.  Update in Interstitial Lung Disease 2020.

Authors:  Anna J Podolanczuk; Alyson W Wong; Shigeki Saito; Joseph A Lasky; Christopher J Ryerson; Oliver Eickelberg
Journal:  Am J Respir Crit Care Med       Date:  2021-06-01       Impact factor: 21.405

9.  Feasibility of online home spirometry in systemic sclerosis-associated interstitial lung disease: a pilot study.

Authors:  Catharina C Moor; Sander I van Leuven; Marlies S Wijsenbeek; Madelon C Vonk
Journal:  Rheumatology (Oxford)       Date:  2021-05-14       Impact factor: 7.580

Review 10.  Minimal clinically important difference in idiopathic pulmonary fibrosis.

Authors:  Mohleen Kang; Lucian Marts; Jordan A Kempker; Srihari Veeraraghavan
Journal:  Breathe (Sheff)       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.